Cardioprotection in breast cancer patients: one size fits all?

Crossroads with the reasoning for using a universal implementation of cardioprotective therapy and a risk-based cardioprotective strategy with neurohormonal blockade in breast cancer patients treated with anthracyclines and/or trastuzumab and no previous cardiovascular disease. ACEi = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker; LVEF = left ventricular ejection fraction. Crossroads with the reasoning for using a universal implementation of cardioprotective therapy and a risk-based cardioprotective strategy with neurohormonal blockade in breast cancer patients treated with anthracyclines and/or trastuzumab and no previous cardiovascular disease. ACEi = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker; LVEF = left ventricular ejection fraction.